BioNxt Solutions Inc.
BNXT
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -89.14% | -92.83% | -89.29% | -92.82% | -41.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.14% | -92.83% | -89.29% | -92.82% | -41.07% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -89.14% | -92.83% | -83.03% | 113.43% | 163.87% |
| SG&A Expenses | -9.12% | -26.84% | -26.02% | -35.07% | 2.52% |
| Depreciation & Amortization | -63.59% | -53.79% | -45.18% | -26.85% | -19.51% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.35% | -34.33% | -20.06% | -30.29% | -5.21% |
| Operating Income | 25.34% | 30.90% | 15.79% | 26.44% | 3.29% |
| Income Before Tax | 28.15% | 31.03% | 50.83% | 53.12% | 38.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.26% | 32.15% | 48.92% | 51.37% | 36.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.26% | 32.15% | 48.92% | 51.37% | 36.10% |
| EBIT | 25.34% | 30.90% | 15.79% | 26.44% | 3.29% |
| EBITDA | 25.10% | 30.52% | 14.95% | 26.48% | 2.98% |
| EPS Basic | 35.88% | 39.20% | 55.92% | 57.83% | 44.86% |
| Normalized Basic EPS | 33.43% | 35.36% | 25.93% | 32.75% | 17.36% |
| EPS Diluted | 35.88% | 39.20% | 55.92% | 57.83% | 44.86% |
| Normalized Diluted EPS | 33.43% | 35.36% | 25.93% | 32.75% | 17.36% |
| Average Basic Shares Outstanding | 9.66% | 12.30% | 14.45% | 15.74% | 18.56% |
| Average Diluted Shares Outstanding | 9.66% | 12.30% | 14.45% | 15.74% | 18.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |